Evolving Targeted Treatment Landscape in Biliary Tract Cancer

The podcast provides peer-to-peer physician perspectives on targeted treatments in BTC, focusing on fibroblast growth factor receptor (FGFR) inhibitors.

Topics include:

• FDA-approved targeted therapies for patients with cholangiocarcinoma
• Mechanism of action of FGFR inhibitors and review of the efficacy and safety data from pivotal trials
• Physician experience with managing common adverse events associated with FGFR inhibitors
• Considerations for the place of FGFR inhibitors in line of therapy, including discussion of new agents currently in development